Results 101 to 110 of about 10,281 (251)
Consumer Psychology Review, EarlyView.Abstract Past research suggests that people exhibit robust waste aversion. However, many consumers routinely feel that they waste not only goods but also time, money, energy, and emotion and would be hard‐pressed to imagine their lives otherwise. Why does consumer waste persist? In this paper, we first propose a definition for consumer waste.
Marissa A. Sharif, Cait Lamberton
wiley +1 more source
Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.Purpose To evaluate cost, outcomes, and incremental cost‐effectiveness of arthroscopic partial meniscectomy comparing visualization using a 1.9 mm distal chip‐on‐tip needlescope versus a standard 4 mm glass rod lens arthroscope. Methods We retrospectively reviewed prospectively collected data (from a larger randomized controlled trial) on patients ...
James H. Lubowitz, Chad Lavender
wiley +1 more source
A sustainable business ecosystem: a case study demonstrating biochar's potential
Biofuels, Bioproducts and Biorefining, EarlyView.Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola +4 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Capacity building in medicines development and regulation in Africa—Overview on recent progress
British Journal of Clinical Pharmacology, EarlyView.Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke +7 more
wiley +1 more source
Economic evaluations of antiobesity medications: A systematic literature review
British Journal of Clinical Pharmacology, EarlyView.The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković +5 more
wiley +1 more source
Family planning services financing in the West African Economic and Monetary Union countries: Trend analysis from 2013 to 2021. [PDF]
J Public Health AfrBelemsaga DY +6 more
europepmc +1 more source